NanoViricides Inc. reported a net loss of $5.74 million for the quarter ended September 30, 2026, compared with a $1.79 million loss in the same period a year earlier. The company generated no revenue and ended the quarter with approximately $2.58 million in cash and cash equivalents.
Higher research and development expenses drove the increased loss as lead drug NV-387 entered two Phase II clinical trials for Ebola and Mpox. NanoViricides reported a quarterly cash burn of $3.64 million and said its funds are insufficient to support planned operations over the next year. The company said these conditions raise substantial doubt about its ability to continue as a going concern.